NORTHBROOK, IL--(Marketwire - June 15, 2010) - Blue Chip, an independent, full-service global marketing agency, announced today the launch of Blue Chip Patient Recruitment (BCPR), a division dedicated to serving pharmaceutical and biotech clients with clinical trial recruitment marketing. This new division reflects Blue Chip's 15 years of continued growth in patient recruitment and leverages the resources of a full-service agency with deep expertise in direct response media, retail brand marketing and clinical site recruitment management. BCPR's first client is BioSante Pharmaceuticals, Inc.
"We are pleased to launch the new division with a compelling, integrated program for BioSante," said Blue Chip Chairman and CEO Stanton Kawer. "Our track record to date has included conducting nearly 600 clinical trials with a 90 percent success rate, making the launch of Blue Chip Patient Recruitment a natural evolution of our business."
BCPR uses a scientific and tested approach to clinical trial marketing that combines proprietary predictive modeling tools with original patient acquisition strategies and continuous evaluation. It leverages Blue Chip's ability to develop the appropriate media and buying mix with firsthand experience in helping physicians effectively manage the site recruitment process to deliver maximum results.
BioSante Pharmaceuticals is an Illinois-based pharmaceutical company focused on developing products for female sexual health and oncology. BCPR is conducting a centrally-managed patient recruitment marketing program for its Phase 3 clinical trial called the Bloom Study. It investigates the safety and efficacy of LibiGel®, an investigational medication for the treatment of Hypoactive Sexual Desire Disorder (HSDD).
"The Bloom Study is very complex with three different protocols, a total of 3,500 - 5, 000 patients and 160 sites located throughout the U.S. and Canada," said Bill Milling, Senior Director of Operations, BioSante Pharmaceuticals. "Blue Chip Patient Recruitment is flawlessly executing a comprehensive and creative marketing campaign, including a web-based solution that is critical to the success of the overall program."
At the outset, the Bloom Study presented several unique patient recruitment challenges: a very narrow patient population, multiple study protocols and a patient population difficult to reach through mass media. BCPR overcame these initial challenges by focusing on cost-effective, results-oriented strategies including a robust digital marketing component. The digital program incorporated behavioral and contextual retargeting strategies and in-depth tracking and analysis of thousands of pre-qualified leads.
"Our approach to the Bloom Study has bucked the 'business as usual' tactics of many of our competitors," said Neil Weisman, Vice President, Blue Chip Patient Recruitment. "It is a shining example of Blue Chip's unique way of tackling patient recruitment marketing and why we are now launching an official division dedicated to this practice."
In addition to BioSante Pharmaceuticals, Blue Chip has developed patient recruitment programs for Novartis, Johnson & Johnson, Pfizer, AstraZeneca, Abbott and Takeda, among others.
About Blue Chip Patient Recruitment
Blue Chip Patient Recruitment is a global, full-service strategic marketing division of Blue Chip, specializing in patient acquisition and retention. For more than 15 years, Blue Chip has used its expertise in direct response media, physician site integration and retail brand marketing to successfully motivate qualified patients to action. Blue Chip has completed nearly 600 clinical trials (with partner companies), resulting in a 90 percent success rate in achieving program goals. For more information, visit www.bcpatientrecruitment.com.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. Additional information is available online at www.biosantepharma.com.